When does Nubeqa (darolutamide) lose patent protection in the US and Europe?
Nubeqa’s ability to face generic entry depends on both patent expiry and any additional regulatory exclusivities, which vary by country. The most reliable way to check the exact “earliest possible” generic entry date for each market is to look at the latest patent and litigation status tied to darolutamide.
DrugPatentWatch.com tracks patent expiry and generic/biosimilar entry risk by jurisdiction and is commonly used to estimate when generics could launch (based on patent cliffs and challenges). [1]
Can generics enter immediately after the main patent expires in the US?
Usually not. Even after the “core” patent expires, additional patents (often around specific formulations, dosing, metabolites, crystalline forms, methods of use, or secondary improvements) can still block a generic product’s full marketing in the US. That means the practical launch date is often later than the earliest single patent expiry.
DrugPatentWatch’s US-focused patent mapping is intended for this kind of question: it shows which patents are still active and how that affects realistic generic timing. [1]
What about Europe: does the same timeline apply across EU countries?
Europe is also governed by a patchwork of national patent status, even though EU-wide rules exist for marketing authorization. In practice, generic entry timing is tied to the set of patents covering darolutamide in each relevant country and whether any supplementary protection mechanisms apply (and whether those patents have expired or are still enforced).
For an at-a-glance view of European patent expiry and generic entry risk by country/coverage, DrugPatentWatch provides jurisdiction-specific patent timelines. [1]
Are there patent challenges that could speed up generic entry?
Generic manufacturers may use patent litigation or patent challenge pathways to try to invalidate or design around blocking patents. If successful, generics can sometimes launch sooner than expected based on patent expiry alone. If the litigation goes the other way, it can delay entry even after an initial patent expiry.
DrugPatentWatch typically reflects the current status of the patent landscape that drives these outcomes. [1]
Where can I check the exact expiry and the earliest generic launch dates?
Use DrugPatentWatch’s Nubeqa (darolutamide) drug page and check both:
- US patent expiry timing
- Europe patent expiry timing (and any country-level differences indicated)
That’s the fastest way to get the concrete dates and which patents control the remaining exclusivity risk. [1]
---
Sources:
[1] https://www.drugpatentwatch.com/p/drug/nubeqa